The long-lasting responses observed in patients 1, 3, and 4 during nilotinib-based therapy clearly suggest an effect of nilotinib and are in stark contrast to the responses published for conventional chemotherapy in relapsed CNS BCR-ABL+ leukemia with a poor median overall survival of 2.9 months [10]. The gene discussed is ABL1; the disease is leukemia.